137005-17-5

Ksg 504 has superior selectivity and affinity to CCK-A receptors and derived from proglumide.

KSG-504 (anhydrous) is a CCK receptor antagonist. KSG-504 (anhydrous) inhibits the development of Ethionine-induced acute pancreatitis in rats and facilitates the regeneration of acinar cells[1].

[1] Okumura Y, et al. Effects of short-term administration of the CCK receptor antagonist, KSG-504, on regeneration of pancreatic acinar cells in acute pancreatitis in rats. J Gastroenterol. 1995 Aug;30(4):493-9. DOI:10.1007/BF02347566